New injection could shrink nasal polyps without surgery
NCT ID NCT07484230
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests itepekimab, an injected antibody, in 20 Japanese adults with chronic sinusitis and nasal polyps that are not well-controlled despite surgery or steroids. The study measures changes in polyp size and nasal congestion over 52 weeks. It aims to see if the drug is safe and effective as a standalone treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
itepekimab (a monoclonal antibody injection)
What this could lead to
If it works, it could offer a new treatment option for people with nasal polyps that are not controlled by current therapies.
What could go wrong
This is a small, early-stage Phase 3 trial with only 20 participants, so results may not apply to everyone. The drug may not work better than placebo or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC RHINOSINUSITIS WITH NASAL POLYPS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••